This is a preview of subscription content, log in via an institution to check access.
References
Byrom WD, Bratty JR, Rotherham NE. A modelling approach to understanding and predicting the hypoglycaemic action of BTS 67 582 in healthy volunteers. Diabet Med 1993 Oct; 10 Suppl. 3: 33–4
Skillman CA, Raskin P. A double-masked placebo-controlled trial assessing effects of various doses of BTS 67 582, a novel insulinotropic agent, on fasting hyperglycemia inNIDDMpatients. Diabetes Care 1997 Apr; 20: 591–6
Raskin P, Skillman C, Weinstein S. Efficacy and dose-response of BTS 67582 in type II diabetes. Diabetes 1997 May; 46 Suppl. 1: 164
Skillman C, Raskin P, Podlecki D, et al. The effects of various doses of BTS 67 582 as compared with placebo in NIDDM patients. Diabetes 1995 May; 44 Suppl. 1: 57A
Byrom WD, Weil A, Brown TJ, et al. BTS 67 582 improves 24h plasma glucose control and postprandial insulin secretion in NIDDM patients. Diabetologia 1996 Aug; 39 Suppl. 1: 44
Rights and permissions
About this article
Cite this article
BTS 67582. Drugs R&D 2, 101–102 (1999). https://doi.org/10.2165/00126839-199902020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902020-00003